Results for tag: "Cell Based Immunotherapy"

Within the field of immune disorders drugs, cell-based immunotherapy represents a burgeoning area focused on harnessing and modifying immune cells to combat various immune-related conditions. This approach typically involves the manipulation of T cells, B cells, or dendritic cells, which are either isolated from a patient or generated de novo, then expanded, activated, or genetically engineered before being reintroduced into the patient's body. Such therapies aim to either bolster the immune response against pathogenic threats or to moderate an overactive immune system in cases of autoimmune diseases. Cell-based immunotherapies have gained increasing attention due to their potential to offer targeted, personalized treatments. They encompass a range of techniques, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapies, tumor-infiltrating lymphocytes (TIL) therapy, and regulatory T-cell (Treg) therapy. While initially cell-based immunotherapies were primarily directed at treating cancer, their scope has expanded to address a variety of immune disorders such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis, and others, reflecting a novel frontier in immunological treatment strategies. Companies that have ventured into the cell-based immunotherapy market include Novartis, Gilead Sciences through its subsidiary Kite Pharma, Bristol Myers Squibb following its acquisition of Celgene, Bluebird Bio, and Regeneron. These industry players are actively involved in the research, development, and commercialization of therapies that seek to Show Less Read more